Retinoids to prevent skin cancer in organ transplant recipients

Kelly, Joan; Sabto, J.; Gurr, F. W.; Bruce, F.

doi:10.1016/0140-6736(91)92292-a

Cited by 60 publications

(34 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the post-transplant population, etretinate, an oral retinoid used in the treatment of psoriasis was associated with a large reduction in the incidence of SCC [9]. Similar to the observation in patients with XP treated with isotretinoin, chemopreventive bene®t was lost quickly after the discontinuation of drug.…”

Section: Retinoid Chemopreventionsupporting

confidence: 56%

Retinoid chemoprevention in patients at high risk for skin cancer*

DiGiovanna

2001

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Patients who develop large numbers of skin cancers suffer increased morbidity and mortality. A high skin cancer risk can result from inherited disorders such as xeroderma pigmentosum (abnormal repair of UV-induced DNA damage) or the nevoid basal cell carcinoma syndrome (tumor suppressor gene abnormality). The efficacy of systemic retinoid skin cancer chemoprevention was first demonstrated in these disorders. Since the mechanism of cancer prevention was not thought to involve correction of the underlying defect causing the disorder, individuals at high risk for new skin cancers from other causes may also benefit from this approach. With the success of organ transplantation, there is a growing population of transplant recipients living long, active lives who also have sustained chronic UV damage. This population is at high risk for developing aggressive squamous cell carcinomas. In this population, extensive skin involvement with human papilloma virus induced warts and actinic keratoses results in difficulty with diagnosis and monitoring for these dangerous malignancies. Patients who have received treatment with agents that cause DNA damage, such as X-radiation, may also have a high skin cancer risk. Retinoid chemoprevention may also be of benefit in the management of selected patients with these iatrogenic conditions. This evolving therapeutic role has heightened the need for the development of new retinoids, with more efficacy and less toxicity, for cancer chemoprevention.

show abstract

Section: Retinoid Chemopreventionsupporting

confidence: 56%

Retinoid chemoprevention in patients at high risk for skin cancer*

DiGiovanna

2001

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

show abstract

“…Similar beneficial effects have been documented in a number of uncontrolled series of between 4 and 16 patients treated for less than 6 months to 5 years. 8,10,[14][15][16][17] In the only randomized, placebo-controlled trial, 19 patients received acitretin for 6 months and had significantly fewer SCCs during this time than did 19 placebo-treated patients. 18 Eleven patients completed a randomized crossover trial in which acitretin produced a significant reduction in SCCs compared with no treatment during 12 months.…”

Section: Resultsmentioning

confidence: 99%

Low-Dose Retinoids in the Prevention of Cutaneous Squamous Cell Carcinomas in Organ Transplant Recipients

Harwood

Leedham-Green²,

Leigh³

et al. 2005

Arch Dermatol

123

View full text Add to dashboard Cite

“…It is vital that any agent under consideration for chemopreventive administration to 'high-risk' individuals over prolonged periods of time should not cause more harm than benefit [152]. As in the skin disease xeroderma pigmentosum, withdrawal of retinoids from transplant patients appears to result in rapid loss of chemopreventive benefit [163]. Although the retinoids, isotretinoin [164] and retinol palmitate [165], may have some degree of activity in preventing second primary cancers in patients with malignancies of the lung and head/neck, compliance is often problematic on account of toxicity.…”

Section: Retinoidsmentioning

confidence: 98%